We are live on ! Find out more

2,915 hedge funds and large institutions have $108B invested in Pfizer in 2026 Q3 according to their latest regulatory filings, with 258 funds opening new positions, 1,154 increasing their positions, 1,218 reducing their positions, and 133 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 258 | Existing positions closed: 133

62% more funds holding in top 10

Funds holding in top 10: 21 → 34 (+13)

16% more call options, than puts

Call options by funds: $3.11B | Put options by funds: $2.68B

2% more funds holding

Funds holding: 2,864 → 2,915 (+51)

5% less repeat investments, than reductions

Existing positions increased: 1,154 | Existing positions reduced: 1,218

1.39% less ownership

Funds ownership: 67.54% → 66.15% (-1.4%)

12% less capital inflows, than outflows

Capital inflows: $5.83B | Capital outflows: $6.63B

Holders
2,915
Holders Change
+51
Holders Change %
+1.78%
% of All Funds
35.46%
Holding in Top 10
34
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+61.9%
% of All Funds
0.41%
New
258
Increased
1,154
Reduced
1,218
Closed
133
Calls
$3.11​B
Puts
$2.68​B
Net Calls
+$426​M
Net Calls Change
+$685​M

PFE Hedge Fund Activity: Q3 2026 in Review

2,915 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2026, worth a combined $108B — up 16% from $92.7B a quarter earlier.

Buyers outnumbered sellers: 258 funds opened new PFE positions and 133 closed out — a net gain of 125 holders — while 1,154 added to existing stakes and 1,218 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $759M. The largest seller was Royal Bank of Canada, cutting an estimated $951M.

  • 2,915 institutional investors held Pfizer (PFE) as of Q3 2026, up from 2,864 in Q2 2026.
  • Funds reported $108B of Pfizer stock for Q3 2026, up 16% quarter-over-quarter.
  • 258 funds opened new Pfizer positions in Q3 2026 and 133 closed out, a net change of +125 holders.
  • The largest Pfizer buyer in Q3 2026 was AQR Capital Management, an estimated $759M added.
  • The largest Pfizer seller in Q3 2026 was Royal Bank of Canada, an estimated $951M sold.

Based on aggregated 13F filings for Q3 2026.